Solid phase synthesis of indinavir and its analogues

Journal of Combinatorial Chemistry

Volumn 2, Issue 5, 2000, Pages 445-446

  Cheng, Yuan ^a   Lu, Zhijian ^a   Chapman, Kevin T ^a   Tata, James R ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG DERIVATIVE; INDINAVIR; PROTEINASE INHIBITOR;

ARTICLE; CHEMICAL STRUCTURE; CHEMISTRY; COMBINATORIAL CHEMISTRY; CONFORMATION; DRUG DESIGN; METHODOLOGY; SYNTHESIS;

COMBINATORIAL CHEMISTRY TECHNIQUES; DRUG DESIGN; HIV PROTEASE INHIBITORS; INDINAVIR; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MOLECULAR STRUCTURE;

EID: 0034268096     PISSN: 15204766     EISSN: None     Source Type: Journal    
DOI: 10.1021/cc000029z     Document Type: Article

References (13)

1. (a) Vacca, J. P.; Dorsery, B. D.; Schleif, W. A.; Levin, R. B.; McDaniel, S. L.; Darke, P. L.; Zugay, J.; Quintero, J. C.; Blanhy, O. M.; Roth, E.; Sardana, V. V.: Schlabach, A. J.; Graham, P. I.; Condra, J. H.; Gotlib, L.; Holloway, M. K.; Lin, J.; Chen, I.-W.; Vastag, K.; Ostovic, D.; Anderson, P. S.; Emini, E. A.; Huff, J. R. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 4096.
2. (b) Vacca, J. P.; Condra, J. H. Drug Discovery Today 1997, 2, 261.
3. (c) Kempf, D. J.; Sham, H. L. Curr. Pharm. Des. 1996, 2, 225.
4. (a) Schock, H. B.; Garsky, V. M.; Kuo, L. C. J. Biol. Chem. 1996, 271, 31957.
5. (b) Deeks, S. G.; Smith, M.; Holodniy, M.; Kahn, J. O. J. Am. Med. Assoc. 1997, 277, 145.
6. For recent reports of other solid phase synthesis of protease inhibitors, see: (a) Kick, E. K.; Ellman, J. A. J. Med. Chem. 1995, 38, 1427.
7. (b) Wang, G. T.; Li, S.; Wideburg, N.; Kraft, G. A.; Kempf, D. J. J. Med. Chem. 1995, 38, 2995.
8. (c) Baker, C. T.; Salituro, F. G.; Court, J. J.; Deininger, D. D.; Kim, E. E.; Li, B.; Novak, P. M.; Tao, B. G.; Pazhanisamy, S.; Schairer, W. C.; Tung, R. D. Bioorg. Med. Chem. Lett. 1998, 8, 3631.
9. (a) Dorsey, B. D.; Levin, R. B.; McDaniel, S. L.; Vacca, J. P.; Guare, J. P.; Darke, P. L.; Zugay, J. A.; Emini, E. A.; Schleif, W. A.; Quintero, J. C.; Lin, J. H.; Chen I.-W.; Holloway, M. K.; Fitzgerald, P. M. D.; Axel, M. G.; Ostovic, D.; Anderson, P. S.; Huff, J. R. J. Med. Chem. 1994, 37, 3443.
10. (b) Askin, D.; Drug Discovery Dev. 1998, 1, 338.
11. (c) Maligres, P. E.; Weissman, S. A.; Upadhyay, V.; Cianciosi, S. J.; Reamer, R. A.; Sager, P. J.; Rossen, K.; Eng, K. K.; Askin, D.; Volante, R. P.; Reider, P. J. Tetrahedron 1996, 52, 3327.
12. Methods used to prepare this intermediate are described in ref 4a.
13. Analysis by HPLC using a 4.6 × 50 mm YMC Combiscreen C18 column (5 μm particle size) with a gradient of 10% acetonitrile/water containing 0.1% TFA to 100% acetonitrile over 2.25 min. Peak areas were integrated at 220 nm.